Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.57
OMER's Cash to Debt is ranked lower than
86% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. OMER: 0.57 )
Ranked among companies with meaningful Cash to Debt only.
OMER' s Cash to Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.20 Max: 23.84
Current: 0.57
0.21
23.84
Equity to Asset -0.54
OMER's Equity to Asset is ranked lower than
96% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OMER: -0.54 )
Ranked among companies with meaningful Equity to Asset only.
OMER' s Equity to Asset Range Over the Past 10 Years
Min: -4.21  Med: -0.54 Max: 0.7
Current: -0.54
-4.21
0.7
F-Score: 3
Z-Score: -11.51
M-Score: 18.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -527.34
OMER's Operating margin (%) is ranked lower than
73% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. OMER: -527.34 )
Ranked among companies with meaningful Operating margin (%) only.
OMER' s Operating margin (%) Range Over the Past 10 Years
Min: -12988.5  Med: -1430.21 Max: -527.34
Current: -527.34
-12988.5
-527.34
Net-margin (%) -555.90
OMER's Net-margin (%) is ranked lower than
75% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. OMER: -555.90 )
Ranked among companies with meaningful Net-margin (%) only.
OMER' s Net-margin (%) Range Over the Past 10 Years
Min: -13668.46  Med: -1389.60 Max: -555.9
Current: -555.9
-13668.46
-555.9
ROA (%) -159.92
OMER's ROA (%) is ranked lower than
93% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. OMER: -159.92 )
Ranked among companies with meaningful ROA (%) only.
OMER' s ROA (%) Range Over the Past 10 Years
Min: -538.37  Med: -120.57 Max: -50.37
Current: -159.92
-538.37
-50.37
ROC (Joel Greenblatt) (%) -8814.76
OMER's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. OMER: -8814.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMER' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8254.24  Med: -3290.08 Max: -2071.66
Current: -8814.76
-8254.24
-2071.66
Revenue Growth (3Y)(%) 13.10
OMER's Revenue Growth (3Y)(%) is ranked higher than
64% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. OMER: 13.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OMER' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -18.75 Max: 13.1
Current: 13.1
0
13.1
EBITDA Growth (3Y)(%) 8.00
OMER's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. OMER: 8.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OMER' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -10.40 Max: 20.1
Current: 8
0
20.1
EPS Growth (3Y)(%) 7.90
OMER's EPS Growth (3Y)(%) is ranked higher than
66% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OMER: 7.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OMER' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -8.80 Max: 19.9
Current: 7.9
0
19.9
» OMER's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

OMER Guru Trades in Q1 2015

Jim Simons 64,435 sh (New)
» More
Q2 2015

OMER Guru Trades in Q2 2015

Jim Simons 136,307 sh (+111.54%)
» More
Q3 2015

OMER Guru Trades in Q3 2015

Paul Tudor Jones 13,000 sh (New)
Jim Simons 12,593 sh (-90.76%)
» More
Q4 2015

OMER Guru Trades in Q4 2015

Joel Greenblatt 10,225 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OMER

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 36.91
OMER's P/S is ranked lower than
74% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. OMER: 36.91 )
Ranked among companies with meaningful P/S only.
OMER' s P/S Range Over the Past 10 Years
Min: 13.85  Med: 42.92 Max: 1667.33
Current: 36.91
13.85
1667.33
Current Ratio 2.29
OMER's Current Ratio is ranked lower than
72% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. OMER: 2.29 )
Ranked among companies with meaningful Current Ratio only.
OMER' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 2.29 Max: 5.47
Current: 2.29
0.49
5.47
Quick Ratio 2.26
OMER's Quick Ratio is ranked lower than
69% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. OMER: 2.26 )
Ranked among companies with meaningful Quick Ratio only.
OMER' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 2.26 Max: 5.47
Current: 2.26
0.46
5.47
Days Inventory 188.22
OMER's Days Inventory is ranked lower than
68% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. OMER: 188.22 )
Ranked among companies with meaningful Days Inventory only.
OMER' s Days Inventory Range Over the Past 10 Years
Min: 182.32  Med: 182.32 Max: 182.32
Current: 188.22
Days Sales Outstanding 167.73
OMER's Days Sales Outstanding is ranked lower than
85% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. OMER: 167.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMER' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.06  Med: 86.46 Max: 265.45
Current: 167.73
36.06
265.45
Days Payable 2.00
OMER's Days Payable is ranked lower than
92% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. OMER: 2.00 )
Ranked among companies with meaningful Days Payable only.
OMER' s Days Payable Range Over the Past 10 Years
Min: 2253.81  Med: 2253.81 Max: 2253.81
Current: 2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.86
OMER's Price/Median PS Value is ranked higher than
59% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. OMER: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
OMER' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.4  Med: 1.02 Max: 38.72
Current: 0.86
0.4
38.72
Price/Graham Number 2.38
OMER's Price/Graham Number is ranked higher than
53% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. OMER: 2.38 )
Ranked among companies with meaningful Price/Graham Number only.
OMER' s Price/Graham Number Range Over the Past 10 Years
Min: 1.47  Med: 2.59 Max: 3.14
Current: 2.38
1.47
3.14
Earnings Yield (Greenblatt) (%) -13.50
OMER's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. OMER: -13.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMER' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 294.5  Med: 381.25 Max: 1464.3
Current: -13.5
294.5
1464.3

More Statistics

Revenue(Mil) $14
EPS $ -2.00
Beta2.95
Short Percentage of Float23.02%
52-Week Range $8.90 - 30.23
Shares Outstanding(Mil)38.26

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 54 105 196
EPS($) -1.17 -0.19 1.02
EPS without NRI($) -1.17 -0.19 1.02

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:MACK, SZSE:002604, XMCE:ROVI, NAS:CEMP, XBRU:ABLX, ROCO:4105 » details
Traded in other countries:3O8.Germany,
Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system. Its product OMS302 or Omidria completed its Phase 3 clinical trial is used for lens replacement surgery and is derived from its PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. In November 2013, the FDA conditionally accepted Omidria as the proposed brand name for OMS302 in the U.S. and in December 2013, the EMA accepted Omidria as the proposed brand name for OMS302 in the EU. In addition to Omidria, the Company has other development programs for pain, inflammation, coagulopathies and disorders of the central nervous system. It has six clinical-stage programs in its pipeline; OMS103 for inflammatory pain following arthroscopic partial meniscectomy surgery, which has completed one Phase 3 trial, its PDE10 inhibitor OMS824 for schizophrenia, which is in a Phase 2 clinical program for patients with stable schizophrenia, its PDE10 inhibitor OMS824 for Huntington's disease, which is in Phase 2 clinical program, its MASP-2 antibody OMS721 for the treatment of thrombotic microangiopathies, which has completed dosing in Phase 1 clinical trial and a Phase 2 clinical program is underway, its PPARγ program, in which three Phase 2 clinical trials are being conducted by its collaborators to evaluate a PPARγ agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine and its PharmacoSurgery product OMS201 for use during urological procedures, including uroendoscopic procedures, that has completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials. As of February 15, 2014, the Company owned or held licenses to a total of 51 issued or allowed patents and 51 pending patent applications in the U.S. and 245 issued or allowed patents and 230 pending patent applications in foreign markets. The Company is subject to regulate under the U.S. and EU governing regulations.
» More Articles for OMER

Headlines

Articles On GuruFocus.com
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Follow Up on a Speculative Options Bet May 27 2011 
Another Two Speculative Options Bets May 13 2011 

More From Other Websites
Omeros Corporation Announces Independent Studies with OMIDRIA® to Be Presented at Upcoming... Apr 26 2016
Omeros Corporation Announces Independent Studies with OMIDRIA® to Be Presented at Upcoming... Apr 26 2016
ETF’s with exposure to Omeros Corp. : April 25, 2016 Apr 25 2016
OMEROS CORP Files SEC form 8-K, Regulation FD Disclosure Apr 22 2016
Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : April 22, 2016 Apr 22 2016
Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases Apr 20 2016
Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases Apr 20 2016
Omeros to Present at the 15th Annual Needham Healthcare Conference Apr 07 2016
Omeros to Present at the 15th Annual Needham Healthcare Conference Apr 07 2016
ETF’s with exposure to Omeros Corp. : April 4, 2016 Apr 04 2016
OMEROS CORP Financials Mar 19 2016
OMEROS CORP Files SEC form 10-K, Annual Report Mar 15 2016
ETF’s with exposure to Omeros Corp. : March 14, 2016 Mar 14 2016
Omeros Corp. :OMER-US: Earnings Analysis: 2015 By the Numbers Mar 10 2016
Edited Transcript of OMER earnings conference call or presentation 8-Mar-16 2:00pm GMT Mar 09 2016
FDA fast-tracks Omeros' kidney drug as company moves into Phase 3 tests Mar 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK